Volume 29, Issue 4, 2020
DOI: 10.24205/03276716.2020.849
Influence of A Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on ACR Scale, C-Reactive Protein, Interleukin-6 And Erythrocyte Sedimentation Rate in Children with Juvenile Idiopathic Arthritis
Abstract
Objective: To evaluate the impact of a recombinant human soluble tumor necrosis factor receptor FC fusion protein (rhuTNFR:Fc) on American College of Rheumatology (ACR) scale, C-reactive protein (CRP), interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR) in children with juvenile idiopathic arthritis (JIA).
Method: 48 patients between 10 -17 years old were recruited in our randomized (1:1) single blinded clinical trial. Among them, 24 received the rhuTNFR:Fc treatment, 24 received the sulfasalazine and methotrexate as control group. Patients’ treatment effetc including ACR score and biomarkers including CRP, IL-6 and ESR were measured at the beginning and 1 month after treatment. Results: rhuTNFR:Fc showed siginifant improvement in the ACR score (P<0.05), decrese in the ESR (22.42 ± 1.2 mm/1h and 26 ± 1.3 mm/1h, P = 0.0455), CRP (62.33 ± 1.1mg/L and 74.54 ± 1.0mg/L, P <0.001) and IL-6 levels (13.46 ± 1.1 ng/mL and 19.88 ± 1.5 ng/mL, P = 0.0012) compared with patients in the control group. Conclusion: rhuTNFR:Fc improved ACR score and decreased inflammatory levels in JIA patients compared with control group.
Keywords
rhuTNFR: Fc, HRQoL, with juvenile idiopathic arthritis, CRP, IL-6, ESR